Novavax said Monday that its anti-COVID vaccine was more than 90% effective, including against variants after a study carried out on nearly 30,000 people in the United States and Mexico.
Follow Israel Hayom on Facebook and Twitter
The vaccine "showed 100% protection against moderate and severe forms of the disease and 90.4% overall," the US biotech company said in a statement, adding that it intended to seek official authorization for the market by the end of the third quarter of 2021.
According to French news agency AFP, Novavax estimates that it will then be able to produce one hundred million doses per month, then one hundred and fifty million by the end of the year.
"Novavax has moved closer to its goal of meeting the persistent and critical global public health demand for new anti-COVID vaccines," said Stanley Erck, president of the company.
Novavax's vaccine, NVX-CoV2373, uses a different technology from those used for vaccines already widely authorized in the world: it is a so-called "subunit" vaccine, based on proteins that trigger an immune response virus-free.
Unlike other vaccines, it does not need to be stored at very cold temperatures, but only between 2 and 8 ° C, which could make it easier to transport and administer in the more vulnerable countries with less developed infrastructure.
Subscribe to Israel Hayom's daily newsletter and never miss our top stories!
More than two billion doses of COVID-19 vaccines have been administered worldwide, but severe inequalities persist between nations.
The richest countries promised one billion doses of anti-COVID vaccines to the poorest nations around the world at the G7 Summit on Friday.
i24NEWS contributed to this report.
